ロード中...
The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice
AIMS: Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a promising therapeutic target for the treatment of hypercholesterolaemia and atherosclerosis. PCSK9 binds to the low density lipoprotein receptor and enhances its degradation, which leads to the reduced clearance of low dens...
保存先:
| 出版年: | Eur Heart J |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Oxford University Press
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5837708/ https://ncbi.nlm.nih.gov/pubmed/28637178 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehx260 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|